Glue4Life/Tampere University

Glue4Life is a next-generation bioink platform for 3D bioprinting of living tissues and organs. Our vision is to shift the paradigm of 3D bioprinting towards clinical solutions to benefit the patients. Currently, Glue4Life is a pending spin-off company, funded by Business Finland and operated under Tampere University, Finland. Glue4Life bioink composition is patent-pending. Female members represent the majority in the Glue4Life team. The team is led by Anni Mörö. Mörö is a co-founder and COO of StemSight Oy – a university spin-off developing cell therapies to treat corneal blindness. Glue4Life team has done pioneer work in the field of 3D bioprinting by manufacturing the first 3D bioprinted human cornea using functional bioinks and human stem cells. Our multidisciplinary team has over a combined 30 years of expertise in the fields of tissue engineering, polymer chemistry and development of human stem cell therapies. We have clinical mind-set with the focus on finding future solutions to patients in need. Team is complimented by a steering group consisting of business professionals from the 3D printing and health tech sector. We are looking for investors and partners to move forward in the clinical development of our platform technology.